

Department of Origin: Integrated Healthcare Services	Effective Date: 01/05/24
Approved by: Chief Medical Officer	Date Approved: 01/04/24
Clinical Policy Document: Special Coverage for COVID-19 Testing After Expiration of the Public Health Emergency	Replaces Effective Clinical Policy Dated: 10/01/23
Reference #: MP/C016	Page: 1 of 7

PURPOSE:

The intent of this clinical policy is to provide coverage for benefits available related to the COVID-19 testing after expiration of the public health emergency.

POLICY:

The public health emergency expired on 5/11/2023.

Aspirus Health Plan continued to waive cost sharing for all individual and group health plans for the following services, when received from participating and non-participating providers, through 12/31/2023.

- Centers for Disease Control (CDC) recommended and FDA-approved testing for the detection of SARS-CoV-2 or the diagnosis of the virus that causes COVID-19; and
- The related office, urgent care, emergency room or telehealth visit which resulted in COVID-19 testing, but only to the extent that such visit is related to the evaluation for and administration of COVID-19 testing

EXCLUSIONS (not limited to):

Refer to member's Certificate of Coverage or Summary Plan Description

CODING:

CPT® or HCPCS

COVID-19 Testing

86328 Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

86408 Neutralizing antibody, severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) (Coronavirus disease [COVID-19]); screen

86409 Neutralizing antibody, severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) (Coronavirus disease [COVID-19]); titer

86413 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative

86769 Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

87426 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19])

87428 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA],

Department of Origin: Integrated Healthcare Services	Effective Date: 01/05/24
Approved by: Chief Medical Officer	Date Approved: 01/04/24
Clinical Policy Document: Special Coverage for COVID-19 Testing After Expiration of the Public Health Emergency	Replaces Effective Clinical Policy Dated: 10/01/23
Reference #: MP/C016	Page: 2 of 7

immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B

87635 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique

87636 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique

87637 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique

87811 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

0202U Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.

0223U Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected

0224U Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed

0225U Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 21 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected

0240U Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected

0241U Infections disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected

0408U Infectious agent antigen detection by bulk acoustic wave biosensor immunoassay, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

C9803 Hospital outpatient clinical visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source

D0606 Molecular testing for a public health related pathogen, including coronavirus

Department of Origin: Integrated Healthcare Services	Effective Date: 01/05/24
Approved by: Chief Medical Officer	Date Approved: 01/04/24
Clinical Policy Document: Special Coverage for COVID-19 Testing After Expiration of the Public Health Emergency	Replaces Effective Clinical Policy Dated: 10/01/23
Reference #: MP/C016	Page: 3 of 7

U0001 Novel Coronavirus Real Time RT-PCR Diagnostic Test Panel This code is only to be used for the tests developed by the Centers for Disease Control and Prevention (CDC)

U0002 nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC Reported by laboratories performing non-CDC laboratory tests for SARS-CoV-2/2019-nCoV (COVID-19)

ICD-10 Diagnosis Code Descriptions

- G44.201 Tension-type headache, unspecified, intractable
- G44.209 Tension-type headache, unspecified, not intractable
- G44.211 Episodic tension-type headache, intractable
- G44.219 Episodic tension-type headache, not intractable
- G44.59 Other complicated headache syndrome
- G44.83 Primary cough headache
- G44.84 Primary exertional headache
- G44.85 Primary stabbing headache
- G44.89 Other headache syndrome
- G93.3 Postviral fatigue syndrome
- J00 Acute nasopharyngitis [common cold] (acute rhinitis; acute coryza; infective rhinitis; nasopharyngitis, NOS)
- J02.8 Acute pharyngitis due to other specified organisms
- J02.9 Acute pharyngitis, unspecified (pharyngitis, NOS; sore throat, NOS)
- J06.0 Acute laryngopharyngitis
- J06.9 Acute upper respiratory infection, unspecified
- J12.81 Pneumonia due to SARS-associated coronavirus
- J12.82 Pneumonia due to coronavirus disease
- J12.89 Other viral pneumonia
- J20.8 Acute bronchitis due to other specified organisms
- J22 Unspecified acute lower respiratory infection
- J40 Bronchitis, not specified as acute or chronic
- J80 Acute respiratory distress syndrome
- J96.00 Acute respiratory failure, unspecified whether with hypoxia or hypercapnia
- J96.01 Acute respiratory failure with hypoxia
- J96.02 Acute respiratory failure with hypercapnia
- J98.8 Other specified respiratory disorders
- M35.81 Multisystem inflammatory syndrome
- M35.89 Other specified systemic involvement of connective tissue
- M54.5 Low back pain
- M54.9 Dorsalgia, unspecified (backache, NOS; back pain, NOS)

Department of Origin: Integrated Healthcare Services	Effective Date: 01/05/24
Approved by: Chief Medical Officer	Date Approved: 01/04/24
Clinical Policy Document: Special Coverage for COVID-19 Testing After Expiration of the Public Health Emergency	Replaces Effective Clinical Policy Dated: 10/01/23
Reference #: MP/C016	Page: 4 of 7

- M62.81 Muscle weakness (generalized)
- M62.838 Other muscle spasm
- M79.10 Myalgia, unspecified site (myofascial pain syndrome)
- M79.11 Myalgia of mastication muscle
- M79.12 Myalgia of auxiliary muscles, head and neck
- M79.18 Myalgia, other site
- M79.89 Other specified soft tissue disorders (polyalgia)
- M79.9 Soft tissue disorder, unspecified
- P35.8 Other congenital viral diseases
- R05 Cough
- R06.02 Shortness of breath
- R06.09 Other forms of dyspnea
- R06.1 Stridor
- R06.2 Wheezing
- R06.3 Periodic breathing
- R06.4 Hyperventilation
- R06.82 Tachypnea, not elsewhere classified
- R06.89 Other abnormalities of breathing
- R06.9 Unspecified abnormalities of breathing
- R07.0 Pain in throat
- R07.89 Other chest pain
- R09.2 Respiratory arrest
- R09.81 Nasal congestion
- R09.82 Postnasal drip
- R10.10 Upper abdominal pain, unspecified
- R10.11 Right upper quadrant pain
- R10.12 Left upper quadrant pain
- R10.13 Epigastric pain
- R10.30 Lower abdominal pain, unspecified
- R10.31 Right lower quadrant pain
- R10.32 Left lower quadrant pain
- R10.33 Periumbilical pain
- R10.84 Generalized abdominal pain
- R10.9 Unspecified abdominal pain
- R11.0 Nausea
- R11.10 Vomiting, unspecified
- R11.11 Vomiting without nausea

Department of Origin: Integrated Healthcare Services	Effective Date: 01/05/24
Approved by: Chief Medical Officer	Date Approved: 01/04/24
Clinical Policy Document: Special Coverage for COVID-19 Testing After Expiration of the Public Health Emergency	Replaces Effective Clinical Policy Dated: 10/01/23
Reference #: MP/C016	Page: 5 of 7

- R11.12 Projectile vomiting
- R11.2 Nausea with vomiting, unspecified
- R19.7 Diarrhea, unspecified
- R19.8 Other specified symptoms and signs involving the digestive system and abdomen
- R23.0 Flushing, excessive blushing
- R25.2 Cramp and spasm
- R43.0 Anosmia
- R43.1 Parosmia
- R43.2 Parageusia
- R43.8 Other disturbances of smell and taste (mixed disturbance of smell and taste)
- R43.9 Unspecified disturbances of smell and taste
- R50.9 Fever, unspecified
- R51 Headache (facial pain NOS)
- R52 Pain, unspecified (acute or generalized pain, NOS)
- R53.1 Weakness
- R53.81 Other malaise (malaise, NOS; debility NOS; general physical deterioration)
- R53.83 Other fatigue (fatigue, NOS; lack of energy; lethargy; tiredness)
- R61 Generalized hyperhidrosis, excessive sweating, night sweats, secondary hyperhidrosis
- R68.83 Chills (without fever)
- U07.1 Other coronavirus as the cause of diseases classified elsewhere
- U099 Post-COVID-19 condition, unspecified
- Z03.818 Encounter for observation for suspected exposure to other biological agents ruled out
- Z11.52 Encounter for screening for COVID-19
- Z11.59 Encounter for screening for other viral diseases
- Z20.822 Contact with and (suspected) exposure to COVID-19
- Z20.828 Contact with and (suspected) exposure to other viral communicable diseases
- Z86.16 Personal history of COVID-19
- Z86.19 Personal history of other infectious and parasitic diseases

General ICD-10-CM Coding Guidelines

- If the provider documents “suspected”, “possible” or “probable” COVID-19, do not assign code U07.1; assign a code(s) explaining the reason for encounter (such as fever, or Z20.828)
- Note: Diagnosis code B34.2, Coronavirus infection, unspecified, would in generally not be appropriate for the COVID-19, because the cases have universally been respiratory in nature, so the site would not be “unspecified”

Department of Origin: Integrated Healthcare Services	Effective Date: 01/05/24
Approved by: Chief Medical Officer	Date Approved: 01/04/24
Clinical Policy Document: Special Coverage for COVID-19 Testing After Expiration of the Public Health Emergency	Replaces Effective Clinical Policy Dated: 10/01/23
Reference #: MP/C016	Page: 6 of 7

The following coding guidance has been developed by CDC and approved by the four organizations that make up the Cooperating Parties: the National Center for Health Statistics, the American Health Information Management Association, the American Hospital Association, and the Centers for Medicare & Medicaid Services.

J82.89 plus U07.1 = pneumonia confirmed due to COVID-19

J20.8 plus U07.1 = acute bronchitis confirmed due to COVID-19

J22 plus U07.1 = COVID-19 documented as being associated with a lower respiratory infection, not otherwise specified (NOS), or an acute respiratory infection, NOS

J98.8 plus U07.1 = COVID-19 documented as being associated with a respiratory infection, NOS

J80 plus U07.1 = ARDS (acute respiratory distress syndrome) due to COVID-19

Z03.818 = concern about a possible exposure to COVID-19, but this ruled out after evaluation

Z20.828 = actual exposure to someone who is confirmed to have COVID-19

Acute respiratory failure

For acute respiratory failure due to COVID-19, assign code U07.1, and code J96.0-, Acute respiratory failure.

Z01.84 Encounter for antibody response examination

Encounter for antibody testing

For an encounter for antibody testing that is not being performed to confirm a current COVID-19 infection, nor is a follow-up test after resolution of COVID-19, assign Z01.84, Encounter for antibody response examination.

Z09 Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm

Follow-up visits after COVID-19 infection has resolved

For individuals who previously had COVID-19 and are being seen for follow-up evaluation, and COVID-19 test results are negative, assign codes Z09, Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm, and Z86.19, Personal history of other infectious and parasitic diseases.

Z38.00- Z38.8 Liveborn infants according to place of birth and type of delivery

COVID-19 Infection in Newborn

For a newborn that tests positive for COVID-19, assign code U07.1, COVID-19, and the appropriate codes for associated manifestation(s) in neonates/newborns in the absence of documentation indicating a specific type of transmission. When coding the birth episode in a newborn record, the appropriate code from category Z38, Liveborn infants according to place of birth and type of delivery, should be assigned as the principal diagnosis.

For a newborn that tests positive for COVID-19 and the provider documents the condition was contracted in utero or during the birth process, assign codes P35.8, Other congenital viral diseases, and U07.1, COVID-19.

Department of Origin: Integrated Healthcare Services	Effective Date: 01/05/24
Approved by: Chief Medical Officer	Date Approved: 01/04/24
Clinical Policy Document: Special Coverage for COVID-19 Testing After Expiration of the Public Health Emergency	Replaces Effective Clinical Policy Dated: 10/01/23
Reference #: MP/C016	Page: 7 of 7

REFERENCES:

1. Integrated Healthcare Services Process Manual: UR015 Use of Medical Policy and Criteria
2. Clinical Policy: Coverage Determination Guidelines (MP/C009)
3. Families First Coronavirus Response Act H.R. 6201. Retrieved from <https://www.congress.gov/bill/116th-congress/house-bill/6201/text>. Accessed 12-26-23.
4. FAQs About Families First Coronavirus Response Act and Coronavirus Aid, Relief, and Economic Security Act Implementation Retrieved from: <https://www.dol.gov/agencies/ebsa/laws-and-regulations/laws/affordable-care-act/for-employers-and-advisers/aca-implementation-faqs>. Accessed 12-26-23.
5. ICD-10-CM Official Guidelines for Coding and Reporting FY 2021 (October 1, 2020 - September 30, 2021). Retrieved from: <https://www.cdc.gov/nchs/data/icd/10cmguidelines-FY2021.pdf> Accessed 12-26-23.
6. Federal Register/ Vol. 85, No. 216/Friday, November 6, 2020/Rules and Regulations. Retrieved from: <https://www.govinfo.gov/content/pkg/FR-2020-11-06/pdf/2020-24332.pdf> Accessed 12-26-23.
7. U.S. Department of Health and Human Services. Fact Sheet: COVID-19 Public Health Emergency Transition Roadmap February 9, 2023. Retrieved from <https://www.hhs.gov/about/news/2023/02/09/fact-sheet-covid-19-public-health-emergency-transition-roadmap.html> Accessed 12-26-23.
8. Expenses related to COVID-19 and Preventive Care for Purposes of High Deductible Health Plans. Notice 2023-37. Retrieved from <https://www.irs.gov/pub/irs-drop/n-23-37.pdf> Accessed 12-26-23.

DOCUMENT HISTORY:

Created Date: 03/03/21
Reviewed Date: 03/03/22, 12/14/22, 12/14/23
Revised Date: 03/15/21, 04/20/21, 04/26/21, 08/23/21, 10/26/21, 12/20/21, 02/02/22, 03/01/22, 04/18/22, 05/26/22, 07/07/22, 09/23/22, 10/20/22, 12/05/22, 12/14/22, 02/01/23, 04/28/23, 06/27/23, 11/28/23, 01/04/24

Nondiscrimination & Language Access Policy

Aspirus Health Plan, Inc. complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, sexual orientation, or gender identity. We do not exclude people or treat them differently because of race, color, national origin, age, disability, sex, sexual orientation, or gender identity.

We will:

Provide free aids and services to people with disabilities to communicate effectively with us, such as:

- Qualified sign language interpreters
- Written information in other formats (large print, audio, accessible electronic formats, other formats)

Provide free language services to people whose primary language is not English, such as:

- Qualified interpreters
- Information written in other languages

If you need these services, contact us at the phone number shown on the inside cover of this contract, your id card, or aspirushealthplan.com.

If you believe that we have failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, sex, sexual orientation, or gender identity, you can file a grievance with:

Nondiscrimination Grievance Coordinator
Aspirus Health Plan, Inc.
PO Box 1062
Minneapolis, MN 55440
Phone: 1.866.631.5404 (TTY: 711)
Fax: 763.847.4010
Email: customerservice@aspirushealthplan.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Nondiscrimination Grievance Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at:

U.S. Department of Health and Human Services
200 Independence Avenue, SW
Room 509F, HHH Building
Washington, D.C. 20201
1-800-368-1019, 800-537-7697 (TDD)

Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

Language Assistance Services

Albanian: KUJDES: Nëse flitni shqip, për ju ka në dispozicion shërbime të asistencës gjuhësore, pa pagesë. Telefononi në 1.866.631.5404 (TTY: 711).

Arabic: تنبيه: إذا كنت تتحدث اللغة العربية، فإن خدمات المساعدة اللغوية متاحة لك مجاناً. اتصل بن اعلى رقم الهاتف 1.866.631.5404 (رقم هاتف الصم والبك : 711)

French: ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelezle 1.866.631.5404 (ATS : 711).

German: ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1.866.631.5404 (TTY: 711).

Hindi: _यान द_ : य_द आप िहंदी बोलते ह_ तो आपके िलए मु_त म_ भाषा सहायता सेवाएं उपल_ध ह_। 1.866.631.5404 (TTY: 711) पर कॉल कर_।

Hmong: LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 1.866.631.5404 (TTY: 711).

Korean: 주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1.866.631.5404 (TTY: 711)번으로 전화해 주십시오.

Polish: UWAGA: Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer 1.866.631.5404 (TTY: 711).

Russian: ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1.866.631.5404 (телетайп: 711).

Spanish: ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1.866.631.5404 (TTY: 711).

Tagalog: PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nangwalang bayad. Tumawag sa 1.866.631.5404 (TTY: 711)

Traditional Chinese: 注意: 如果您使用繁體中文, 您可以免費獲得語言援助服務。請致電 1.866.631.5404 (TTY:711)。

Vietnamese: CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1.866.631.5404 (TTY: 711).

Pennsylvania Dutch: Wann du Deitsch (Pennsylvania German / Dutch) schwetzsch, kannscht du mitaus Koschte ebbergricke, ass dihr helft mit die englisch Schprooch. Ruf selli Nummer uff: Call 1.866.631.5404 (TTY: 711).

Lao: ໄປ່ດຊາຍ: ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໄດຍບໍ່ເສັຽຄ່າ, ແມ່ນມີພ້ອມໃຫ້ທ່ານ. ໂທ 1.866.631.5404 (TTY:711).